Sun Pharma to acquire Organon at $11.75-bn enterprise valuation

The firm has signed a definitive agreement, under which Sun Pharma will acquire all outstanding shares of Organon for $14 per share in an all-cash transaction with an enterprise valuation of $11.75 billion